# Salem Partners

> Salem Partners is a VC fund backing Biotechnology and Health Care. See 15 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Los Angeles, United States
- Total investments: 15
- Last investment: May 2026
- Lead investor: 33%
- Last fund: Oct 2019
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/salem-partners-llc
- Website: http://www.salempartners.com

Salem Partners is a leading Los Angeles-based investment bank and wealth management firm. They build relationships using their judgment, objectivity and expertise to create significant long-term value for their clients.

## Contacts

5 contacts available for Salem Partners. Shizune tracks 2 team members at Salem Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/salem-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 40% |
| Health Care | 4 | 27% |
| Software | 3 | 20% |
| Medical | 2 | 13% |
| Therapeutics | 2 | 13% |

31 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 27% |
| Series B | 3 | 20% |
| Series D | 3 | 20% |
| Convertible Note | 2 | 13% |
| Series C | 1 | 7% |

6 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| William B. Witte | President | 0 | https://shizune.co/investors/profile/william-b-witte |
| John Dyett | Co-Founder and Managing Director | 1 | https://shizune.co/investors/profile/john-dyett |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Rightsline | RightsLine provides software solutions to media and entertainment companies who need to track the full lifecycle of licensing and distribution deals around the world. Our solutions provide a transparent, codified way for content owners and content distributors to know exactly what the have to sell, on what terms, and for how long.Our software isbuilt on industry leading technology in a true multi tenant infrastructure, meaning our cost to deploy is a fraction of our competition.Our clients span across film, television, music, and publishing, but they all have one thing in common; the need to track the licensing deals they've done, when they expire, and what the terms and payments need to be.Leveraging cloud technologies and bringing an intuitive UI, RightsLine can handle any size library and any level of rights complexity. Examples of our client success cases include Disney, Turner, Google, Amazon Studios, Hulu, and a hundred others from the largest in the world to a single distributor. |  | Private Equity | May 27, 2026 |  |
| Fabric | Fabric is a cloud platform that enables customers to manage editorial, technical, and other metadata for television shows, movies, documentaries, games, and other media. With Fabric, you can easily connect your catalogue to new platforms, transform internal data processes, and deliver dramatically improved viewer and user experiences. |  | Series B | Dec 01, 2022 |  |
| Form Bio | Form Bio provides a variety of features, including workflows, data management, collaboration, data visualisation, and workflow catalogue. It provides solutions for lab directors, biotech, pharma, academics, and other fields. | $30M | Series A | Sep 27, 2022 |  |
| Onconano Medicine | OncoNano Medicine is a biotech company that develops nanotechnology-enabled fluorescent probes to help cancer surgeons visualize tumors during surgery, allowing them to excise tumors more precisely. The fluorescent sensor targets the different pH signals, thus making them glow so they are easier to distinguish from normal tissue.OncoNano Medicineis a UTSW spinoff company based in Dallas, Texas. | $68.4M | Convertible Note | Oct 02, 2021 |  |
| Fabric | Fabric is a cloud platform that enables customers to manage editorial, technical, and other metadata for television shows, movies, documentaries, games, and other media. With Fabric, you can easily connect your catalogue to new platforms, transform internal data processes, and deliver dramatically improved viewer and user experiences. |  | Series A | Jun 01, 2021 |  |
| Onconano Medicine | OncoNano Medicine is a biotech company that develops nanotechnology-enabled fluorescent probes to help cancer surgeons visualize tumors during surgery, allowing them to excise tumors more precisely. The fluorescent sensor targets the different pH signals, thus making them glow so they are easier to distinguish from normal tissue.OncoNano Medicineis a UTSW spinoff company based in Dallas, Texas. | $23.7M | Series A | Jul 09, 2019 |  |
| Rightsline | RightsLine provides software solutions to media and entertainment companies who need to track the full lifecycle of licensing and distribution deals around the world. Our solutions provide a transparent, codified way for content owners and content distributors to know exactly what the have to sell, on what terms, and for how long.Our software isbuilt on industry leading technology in a true multi tenant infrastructure, meaning our cost to deploy is a fraction of our competition.Our clients span across film, television, music, and publishing, but they all have one thing in common; the need to track the licensing deals they've done, when they expire, and what the terms and payments need to be.Leveraging cloud technologies and bringing an intuitive UI, RightsLine can handle any size library and any level of rights complexity. Examples of our client success cases include Disney, Turner, Google, Amazon Studios, Hulu, and a hundred others from the largest in the world to a single distributor. |  | Series D | Jun 14, 2019 |  |
| Lucid Sight | Lucid Sight is a computer software company that specializes in blockchain, augmented reality, and virtual reality. The company focuses on developing innovative monetization and marketing platforms for brands and game developers using emerging technologies. | $6M | Series B | Apr 02, 2019 |  |
| AsclepiX Therapeutics | AsclepiX Therapeutics represents the next generation of biologics and drug development technology. They use bioinformatics and systems biology methods to design classes of short biomimetic anti-angiogenic (anti-neovascular), and anti-lymphangiogenic peptides. They also use the latest developments in biomaterials and drug delivery to designlong-lasting biodegradable nano and microparticles to deliver these biomimetic therapeutic peptides throughout the body.AsclepiX Therapeutics utilizes its platform technology for indications in ophthalmology, oncology, and for other angiogenesis and lymphangiogenesis-dependent diseases. | $5M | Convertible Note | Nov 13, 2018 |  |
| Onconano Medicine | OncoNano Medicine is a biotech company that develops nanotechnology-enabled fluorescent probes to help cancer surgeons visualize tumors during surgery, allowing them to excise tumors more precisely. The fluorescent sensor targets the different pH signals, thus making them glow so they are easier to distinguish from normal tissue.OncoNano Medicineis a UTSW spinoff company based in Dallas, Texas. | $11.7M | Series A | May 17, 2018 |  |

10 of 15 investments shown.

## Co-investors
- [RiverVest](https://shizune.co/investors/profile/rivervest) — VC Fund, 2 deals together
- [Accuitive Medical Ventures](https://shizune.co/investors/profile/accuitive-medical-ventures) — VC Fund, 1 deal together
- [Adage Capital Management](https://shizune.co/investors/profile/adage-capital-management) — VC Fund, 1 deal together
- [Animoca Brands](https://shizune.co/investors/profile/animoca-brands-corporation) — VC Fund, 1 deal together
- [Barer & Son Capital](https://shizune.co/investors/profile/barer-son-capital) — VC Fund, 1 deal together
- [BreakawayGrowth Fund](https://shizune.co/investors/profile/breakaway-growth-fund) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Salem Partners invest in?

Salem Partners invests primarily in Biotechnology, Health Care and Software startups, most often at Series A and Series B stage. Most of the 15 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Salem Partners?

Public channels for Salem Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Salem Partners?

The team at Salem Partners includes William B. Witte (President) and John Dyett (Co-Founder and Managing Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co